These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 21498151)

  • 1. Lower CD4 cell count and higher virus load, but not antiretroviral drug resistance, are associated with AIDS-defining events and mortality: an ACTG Longitudinal Linked Randomized Trials (ALLRT) analysis.
    Swindells S; Jiang H; Mukherjee AL; Winters M; Bosch RJ; Katzenstein D; Aids Clinical Trials Group
    HIV Clin Trials; 2011; 12(2):79-88. PubMed ID: 21498151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between CD4+ T-cell counts/HIV-1 RNA plasma viral load and AIDS-defining events among persons followed in the ACTG longitudinal linked randomized trials study.
    Smurzynski M; Wu K; Benson CA; Bosch RJ; Collier AC; Koletar SL
    J Acquir Immune Defic Syndr; 2010 Sep; 55(1):117-27. PubMed ID: 20622677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team.
    Hughes MD; Johnson VA; Hirsch MS; Bremer JW; Elbeik T; Erice A; Kuritzkes DR; Scott WA; Spector SA; Basgoz N; Fischl MA; D'Aquila RT
    Ann Intern Med; 1997 Jun; 126(12):929-38. PubMed ID: 9182469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic importance of changes in CD4+ cell count and HIV-1 RNA level in women after initiating highly active antiretroviral therapy.
    Anastos K; Barrón Y; Cohen MH; Greenblatt RM; Minkoff H; Levine A; Young M; Gange SJ
    Ann Intern Med; 2004 Feb; 140(4):256-64. PubMed ID: 14970148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of AIDS-defining events at initiation of antiretroviral therapy on long-term mortality of HIV/AIDS patients in Southwestern China: a retrospective cohort study.
    Huang Y; Zhou O; Zheng Z; Xu Y; Shao Y; Qin C; Qin F; Lai J; Liu H; Chen R; Ye L; Liang H; Qin X; Jiang J
    AIDS Res Ther; 2020 Jul; 17(1):44. PubMed ID: 32680536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of maintaining highly active antiretroviral therapy on AIDS events among patients with late-stage HIV infection and inadequate response to therapy.
    Gandhi T; Wei W; Amin K; Kazanjian P
    Clin Infect Dis; 2006 Mar; 42(6):878-84. PubMed ID: 16477568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical impact of continuing to prescribe antiretroviral therapy in patients with advanced AIDS who manifest no virologic or immunologic benefit.
    Wohl DA; Kendall MA; Feinberg J; Alston-Smith B; Owens S; Chafey S; Marco M; Maxwell S; Benson C; Keiser P; van der Horst C; Jacobson MA;
    PLoS One; 2013; 8(11):e78676. PubMed ID: 24260125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of AIDS-defining events among advanced naïve patients after HAART.
    Torti C; Lapadula G; Maggiolo F; Casari S; Suter F; Minoli L; Pezzoli C; Pietro MD; Migliorino G; Quiros-Roldan E; Ladisa N; Sighinolfi L; Gatti F; Carosi G;
    HIV Clin Trials; 2007; 8(3):112-20. PubMed ID: 17621458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170.
    Skiest DJ; Su Z; Havlir DV; Robertson KR; Coombs RW; Cain P; Peterson T; Krambrink A; Jahed N; McMahon D; Margolis DM;
    J Infect Dis; 2007 May; 195(10):1426-36. PubMed ID: 17436222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutations linked to drug resistance, human immunodeficiency virus type 1 biologic phenotype and their association with disease progression in children receiving nucleoside reverse transcriptase inhibitors.
    Englund JA; Raskino C; Vavro C; Palumbo P; Ross LL; McKinney R; Nikolic-Djokic D; Colgrove RC; Baker CJ;
    Pediatr Infect Dis J; 2004 Jan; 23(1):15-22. PubMed ID: 14743040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death.
    Holkmann Olsen C; Mocroft A; Kirk O; Vella S; Blaxhult A; Clumeck N; Fisher M; Katlama C; Phillips AN; Lundgren JD;
    HIV Med; 2007 Mar; 8(2):96-104. PubMed ID: 17352766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AIDS clinical trials group longitudinal linked randomized trials (ALLRT): rationale, design, and baseline characteristics.
    Smurzynski M; Collier AC; Koletar SL; Bosch RJ; Wu K; Bastow B; Benson CA
    HIV Clin Trials; 2008; 9(4):269-82. PubMed ID: 18753121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection.
    Baker JV; Peng G; Rapkin J; Abrams DI; Silverberg MJ; MacArthur RD; Cavert WP; Henry WK; Neaton JD;
    AIDS; 2008 Apr; 22(7):841-8. PubMed ID: 18427202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in plasma HIV RNA levels and CD4+ lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. VA Cooperative Study Group on AIDS.
    O'Brien WA; Hartigan PM; Daar ES; Simberkoff MS; Hamilton JD
    Ann Intern Med; 1997 Jun; 126(12):939-45. PubMed ID: 9182470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maintaining antiretroviral therapy reduces the risk of AIDS-defining events in patients with uncontrolled viral replication and profound immunodeficiency.
    Kousignian I; Abgrall S; Grabar S; Mahamat A; Teicher E; Rouveix E; Costagliola D;
    Clin Infect Dis; 2008 Jan; 46(2):296-304. PubMed ID: 18171266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial.
    Gulick RM; Ribaudo HJ; Shikuma CM; Lalama C; Schackman BR; Meyer WA; Acosta EP; Schouten J; Squires KE; Pilcher CD; Murphy RL; Koletar SL; Carlson M; Reichman RC; Bastow B; Klingman KL; Kuritzkes DR;
    JAMA; 2006 Aug; 296(7):769-81. PubMed ID: 16905783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD4 cell count and viral load-specific rates of AIDS, non-AIDS and deaths according to current antiretroviral use.
    Mocroft A; Phillips AN; Gatell J; Horban A; Ledergerber B; Zilmer K; Jevtovic D; Maltez F; Podlekareva D; Lundgren JD;
    AIDS; 2013 Mar; 27(6):907-918. PubMed ID: 23698060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of AIDS and death at given HIV-RNA and CD4 cell count, in relation to specific antiretroviral drugs in the regimen.
    Olsen CH; Gatell J; Ledergerber B; Katlama C; Friis-Møller N; Weber J; Horban A; Staszewski S; Lundgren JD; Phillips AN;
    AIDS; 2005 Feb; 19(3):319-30. PubMed ID: 15718843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initial plasma HIV-1 RNA levels and progression to AIDS in women and men.
    Sterling TR; Vlahov D; Astemborski J; Hoover DR; Margolick JB; Quinn TC
    N Engl J Med; 2001 Mar; 344(10):720-5. PubMed ID: 11236775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of Severe Non AIDS Events Is Increased among Patients Unable to Increase their CD4+ T-Cell Counts >200+/μl Despite Effective HAART.
    Lapadula G; Chatenoud L; Gori A; Castelli F; Di Giambenedetto S; Fabbiani M; Maggiolo F; Focà E; Ladisa N; Sighinolfi L; Di Pietro M; Pan A; Torti C;
    PLoS One; 2015; 10(5):e0124741. PubMed ID: 26020949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.